MedTrace Logo

Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)

NCT05455931 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2026-06-26

No results posted yet for this study

Summary

This is a prospective, observational, non-interventional, international, multi-center, mixed methods study that will involve the integration of quantitative and qualitative data in patients with MF/SS treated with Poteligeo.

Conditions

  • Mycosis Fungoides and Sézary Syndrome

Interventions

DRUG

Poteligeo

Poteligeo treatment will be used as prescribed by the Investigator in accordance with the terms of the reimbursed indication within the relevant country. The assignment of the patient to a particular therapeutic strategy falls within current practice and the prescription of Poteligeo is clearly separated from the decision to include the patient in the study.

Sponsors & Collaborators

  • Kyowa Kirin Pharmaceutical Development Ltd

    lead INDUSTRY

Principal Investigators

  • Kyowa Kirin Medical Affairs Division · Kyowa Kirin Medical Affairs Division

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-09
Primary Completion
2025-08-07
Completion
2025-08-07

Countries

  • United States
  • Italy
  • Netherlands
  • Spain
  • United Arab Emirates
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05455931 on ClinicalTrials.gov